Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

C. Taylor, Peter; Keystone, Edward; van der Heijde, Désirée; E. Weinblatt, Michael; Morales, Liliana; Reyes Gonzaga, Jaime; S. Yаkushin, S.; Ishii, Taeko; Emoto, Kahaku; D. Beattie, Scott; Arora, Vipin; Gaich, C.; Rooney, Terence; Schlichting, Douglas; L. Macias, William; de Bono, Stephanie; Tanaka, Yoshiya

doi:10.1056/nejmoa1608345

Public

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

Published in New England Journal of Medicine • Feb 15, 2017

Authors:

Peter C. Taylor

Edward Keystone

Désirée van der Heijde

Abstract

BACKGROUND: Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that may have therapeutic value in patients with rheumatoid arthritis. METHODS: We conducted a 52-week, phase 3, double-blind, placebo- and active-controlled trial in which 1307 patients with active rheumatoi...

Subject

Medicine

Adalimumab

Rheumatoid arthritis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!